Skip to main content

Peer Review reports

From: Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma

Original Submission
11 May 2020 Submitted Original manuscript
28 Jun 2020 Author responded Author comments - Lin Shui
Resubmission - Version 2
28 Jun 2020 Submitted Manuscript version 2
Publishing
1 Jul 2020 Editorially accepted
9 Jul 2020 Article published 10.1186/s12885-020-07126-3

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us